909 related articles for article (PubMed ID: 8027577)
21. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
Wong HK
G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
[TBL] [Abstract][Full Text] [Related]
22. Increased interleukin-36γ expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/Sézary syndrome.
Otobe S; Sugaya M; Nakajima R; Oka T; Takahashi N; Kabasawa M; Miyagaki T; Asano Y; Sato S
J Dermatol; 2018 Apr; 45(4):468-471. PubMed ID: 29314201
[TBL] [Abstract][Full Text] [Related]
23. [Clinicopathological differential diagnosis of mycosis fungoides/Sézary syndrome from the cutaneous type of adult T-cell leukemia/lymphoma].
Johno M; Ono T
Nihon Rinsho; 2000 Mar; 58(3):660-4. PubMed ID: 10741142
[TBL] [Abstract][Full Text] [Related]
24. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
Mehdi SJ; Moerman-Herzog A; Wong HK
BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
[TBL] [Abstract][Full Text] [Related]
25. Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4.
Showe LC; Fox FE; Williams D; Au K; Niu Z; Rook AH
J Immunol; 1999 Oct; 163(7):4073-9. PubMed ID: 10491012
[TBL] [Abstract][Full Text] [Related]
26. Cytokine gene profile in circulating blood mononuclear cells from patients with systemic lupus erythematosus: increased interleukin-2 but not interleukin-4 mRNA.
Horwitz DA; Wang H; Gray JD
Lupus; 1994 Oct; 3(5):423-8. PubMed ID: 7841998
[TBL] [Abstract][Full Text] [Related]
27. [Mycosis fungoides and Sézary syndrome : a systematic review].
André F; Guenova E; Blanchard G
Rev Med Suisse; 2022 Mar; 18(775):578-589. PubMed ID: 35353453
[TBL] [Abstract][Full Text] [Related]
28. Mycosis fungoides and Sézary's syndrome show distinct histomorphological features.
Imai S; Burg G; Braun-Falco O
Dermatologica; 1986; 173(3):131-5. PubMed ID: 3770259
[TBL] [Abstract][Full Text] [Related]
29. Demonstration of a subpopulation of Ia+ T-helper cells in mycosis fungoides and the Sézary syndrome.
Hofman FM; Meyer PR; Yanagihara E; Modlin RL; Rea TH; Parker JW; Lukes RJ; Taylor CR
Am J Dermatopathol; 1983 Apr; 5(2):135-43. PubMed ID: 6224436
[TBL] [Abstract][Full Text] [Related]
30. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
31. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
32. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
Wang L; Rocas D; Dalle S; Sako N; Pelletier L; Martin N; Dupuy A; Tazi N; Balme B; Vergier B; Beylot-Barry M; Carlotti A; Bagot M; Battistella M; Chaby G; Ingen-Housz-Oro S; Gaulard P; Ortonne N
Br J Dermatol; 2022 Dec; 187(6):970-980. PubMed ID: 35895386
[TBL] [Abstract][Full Text] [Related]
33. Various cytokines modulate ICAM-1 shedding on melanoma- and CTCL-derived cell lines: inverse regulation of ICAM-1 shedding in a Sézary cell line by interferon-gamma.
Dummer R; Sigg-Zemann S; Kalthof K; Muletta S; Meyer JC; Burg G
Dermatology; 1994; 189(2):120-4. PubMed ID: 7915555
[TBL] [Abstract][Full Text] [Related]
34. T cell subset heterogeneity in a series of patients with mycosis fungoides and Sézary syndrome.
Piepkorn M; Marty J; Kjeldsberg CR
J Am Acad Dermatol; 1984 Sep; 11(3):427-32. PubMed ID: 6237132
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides.
Cetinözman F; Jansen PM; Vermeer MH; Willemze R
Arch Dermatol; 2012 Dec; 148(12):1379-85. PubMed ID: 23247480
[TBL] [Abstract][Full Text] [Related]
36. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
37. Diminished CD3 expression is useful for detecting and enumerating Sézary cells.
Edelman J; Meyerson HJ
Am J Clin Pathol; 2000 Sep; 114(3):467-77. PubMed ID: 10989648
[TBL] [Abstract][Full Text] [Related]
38. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
Brender C; Nielsen M; Kaltoft K; Mikkelsen G; Zhang Q; Wasik M; Billestrup N; Odum N
Blood; 2001 Feb; 97(4):1056-62. PubMed ID: 11159537
[TBL] [Abstract][Full Text] [Related]
39. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
40. Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis.
Wada DA; Wilcox RA; Weenig RH; Gibson LE
J Cutan Pathol; 2010 May; 37(5):535-41. PubMed ID: 19674197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
